JAMA Articles Suggest Non-Inferiority Trials Are, In Fact, Sometimes Inferior
This article was originally published in The Gray Sheet
Executive Summary
Non-inferiority and equivalence trials are often poorly conducted and poorly reported, according to a series of articles in the Journal of the American Medical Association that could have particular implications for device firms
You may also be interested in...
FDA Defines Ground Rules For Evolving DES Clinical Trial Paradigm
Foreign drug-eluting stent trial strategies should be discussed with FDA at pre-IDE meetings to ensure that data outside the U.S. will be acceptable for premarket submissions, CDRH Division of Cardiovascular Devices Director Bram Zuckerman recommends
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.